Related Experiment Video

Updated: Dec 6, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.9K

Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1

Jing Cai1, Kaiying Lin1, Wei Cai1

  • 1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

Molecular Oncology
|October 10, 2020
PubMed

Insights

RAS mutations enhance oncolytic virus M1

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Oncolytic viruses selectively kill cancer cells, with selectivity influenced by oncogenic mutations.
  • The precise mechanisms linking M1 oncolytic virus selectivity to cancer signaling pathways remain unclear.

Purpose of the Study:

  • To investigate the role of RAS mutations in M1 oncolytic virus replication and efficacy.
  • To elucidate the impact of the RAS/RAF/MEK signaling pathway on M1 virus infection.
  • To identify downstream factors mediating M1's interaction with cancer cells.

Main Methods:

  • RAS mutation analysis in cancer models.
  • Inhibition of the RAS/RAF/MEK signaling axis.
  • Transcriptome analysis and RNA interference screening.
  • Gain- and loss-of-function experiments for CDKN1A.
  • TCGA data mining and tissue microarray analysis.

Main Results:

  • RAS mutations significantly promote M1 replication and oncolytic effects in cancer.
  • Inhibiting the RAS/RAF/MEK pathway suppresses M1 infection and cytopathic effects.
  • RAS inhibition upregulates the type I interferon antiviral response.
  • CDKN1A was identified as a key downstream factor inhibiting M1 viral infection.
  • CDKN1A deficiency is common in human cancers, indicating broad clinical potential for M1.

Conclusions:

  • RAS signaling is crucial for M1 oncolytic virus efficacy in cancer.
  • Virotherapy offers a viable treatment strategy for RAS-driven cancers.
  • CDKN1A serves as a potential biomarker for personalized M1 virotherapy.
Keywords:
CDKN1AM1RASbiomarkercancer accurate therapyoncolytic virus

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.8K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.6K